At AAIC 2013, researchers present the latest genetic risk factors for Alzheimer's disease.
Researchers have long assumed that people with familial Alzheimer’s disease make too much Aβ42 in the brain, but they lacked proof.
The insoluble proteome from Alzheimer’s brains points to RNA processing proteins as a novel component of aggregates.
Amyloid fibrils seeded by Alzheimer’s brain extracts indicate that Aβ forms specific strains in different individuals.
A cancer drug-turned-Alzheimer’s prospect now appears to have potential against a third disease, reportedly protecting animal models from Parkinson’s damage.
New data questions whether LRRK2’s kinase activity contributes to Parkinson’s, finding instead that absolute levels of the protein matter more.
Neuroligin, a synapse-building protein previously tied to autism, may play a part in Alzheimer’s disease through neuroinflammation and DNA transcription.
Neurons in mice spit out monomeric tau when electrically stimulated, hinting that neural activity may help drive the spread of pathological forms of tau in the brain.
Superficial siderosis, a leakage of blood matter onto the outer surface of the cerebral cortex, may be linked to AD and other dementias.
Hardening of the arteries correlated with greater amyloid deposition in a longitudinal study, strengthening ties between cardiovascular disease and Alzheimer’s.
The NIH announced $45 million in new funding to support trials in preclinical Alzheimer’s populations, as well as efforts to identify new therapeutic targets.
Tau and amyloid PET tracers demonstrate potential to sharpen the diagnosis of Alzheimer’s disease and frontotemporal dementias.
Conformations of misfolded tau survive injection from one mouse to the next, a property shared by prions.
A Phase 2 trial suggests that the drug PBT2 is generally safe for Huntington’s patients. The drug's sponsor says it may have improved cognition, though experts remain unconvinced.
It’s a scenario familiar to many clinicians: A patient diagnosed with mild cognitive impairment asks if he or she will eventually develop Alzheimer’s disease.